Skip to content

Subscribe Follow on LinkedIn

Archive

Dr. Adil Ali

Dr. Adil Ali

February 2026

6: IND Accepted: Affinia Advances Gene Therapy for BAG3 DCM with FDA

February 2026

5: ImmunityBio Begins Phase 2 Evaluation of Chemotherapy-Free NK-Cell Combination in Indolent Lymphomas

February 2026

5: Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

February 2026

5: SpyGlass Pharma Announces Pricing of Initial Public Offering

February 2026

5: Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

February 2026

4: Avidity details spin-off of precision cardiology assets as Novartis deal progresses

February 2026

4: enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 2026

4: Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

February 2026

3: MassBio Applauds Passage of Appropriations Bill, $400 Million Increase in NIH Funding

February 2026

3: Guardant Health to Participate in Upcoming Investor Conferences

February 2026

3: Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies

February 2026

3: Piramal Pharma Solutions commercializes tablet-in-capsule drug delivery capability

February 2026

3: NYSE listing and China licensing deal signal AstraZeneca’s two-market strategy

February 2026

3: Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

February 2026

3: Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients

February 2026

3: Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

February 2026

2: FDA approvals - January 2026

February 2026

2: Avidity Biosciences Announces Expected Record Date for Spin-Off

February 2026

2: ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 2026

2: Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

February 2026

2: Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

February 2026

2: Why Flatiron is betting on data quality, not hype, to power the next era of cancer care

January 2026

30: “Efficacy with safety”: the north star behind Outpace’s next-gen engineered cell therapies

January 2026

29: Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

January 2026

29: Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

January 2026

29: Lexicon Announces Proposed Public Offering of Common Stock

January 2026

29: Opentrons Global Robotics Chief, James Atwood, Named Chief Executive Officer

January 2026

29: From diagnostics to drug development: Scipher Medicine’s three-track strategy for high-impact immunology

January 2026

28: Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation

January 2026

28: nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B

January 2026

28: Why Novellia thinks the best biopharma data strategy starts with patients, not pipelines

January 2026

27: Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

January 2026

27: Mark Lappe’s lean biotech model: smaller teams, bigger wins

January 2026

26: The lab-data marketplace powering precision medicine’s next wave

January 2026

23: Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

January 2026

23: Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

January 2026

23: ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 2026

23: Biotech's new superstructure: Vivodyne's bid to turn human tissues into scalable, searchable data

January 2026

22: Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 2026

22: Inside Cellares’ $380M push to automate cell therapy manufacturing

January 2026

21: Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

January 2026

21: Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

January 2026

21: Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

January 2026

21: Why Allucent says its global footprint is now a competitive edge in early-stage trials

January 2026

20: Behind the Breakthrough: MassBio’s 2026 State of Possible Conference

January 2026

20: enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

January 2026

20: Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes

January 2026

20: ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 2026

20: Building for zero failure: How 4G Clinical is redefining trial supply management

January 2026

19: Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 2026

19: How DNAnexus is enabling precision medicine from research to the point of care

January 2026

16: ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

January 2026

16: ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

January 2026

16: ‘The moat is data’: Marc Tessier-Lavigne on building an AI-native drug company

January 2026

15: ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% Increase Year-Over-Year

January 2026

15: Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

January 2026

15: The long game in cancer screening: Freenome’s data-first strategy

January 2026

15: Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

January 2026

14: Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

January 2026

14: Why Trevi Therapeutics’ Jennifer Good believes treating cough means targeting the brain

January 2026

13: ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

January 2026

13: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

January 2026

13: Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

January 2026

13: Inside nChroma Bio’s push to deliver a functional cure for Hepatitis B

January 2026

12: NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

January 2026

12: IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares’ Automated Platforms

January 2026

12: Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands

January 2026

12: Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO

January 2026

12: Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

January 2026

12: Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 2026

12: Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

January 2026

12: Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

January 2026

12: Geron Corporation Provides 2026 Financial Guidance

January 2026

12: Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

January 2026

12: How Quince plans to scale a rare-disease platform built on patients’ own blood

January 2026

9: Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

January 2026

9: How Genomenon finds order in 11 million scientific papers

January 2026

9: Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

January 2026

9: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

January 2026

9: Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

January 2026

8: Massachusetts biopharma pipeline surges 14% as companies double down on innovation

January 2026

8: Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

January 2026

8: Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy

January 2026

8: The physics mindset behind one of biotech’s fastest-growing diagnostics companies

January 2026

7: Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

January 2026

7: Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 2026

7: Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 2026

7: The first inning of a new research paradigm: Emulate, Inc. and the rise of organ-on-a-chip technology

January 2026

7: Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 2026

6: MassBio and Kendall Square Association Announce Strategic Partnership

January 2026

6: Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

January 2026

6: SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

January 2026

6: Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

January 2026

6: DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

January 2026

6: 3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors

January 2026

5: Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

January 2026

5: Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 2026

2: FDA approvals - December 2025

December 2025

29: ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of the “100 Most Influential People in Oncology in 2025”

December 2025

29: Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference